Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2

Louis Grandjean, Anja Saso, View ORCID ProfileArturo Torres Ortiz, Tanya Lam, James Hatcher, Rosie Thistlethwayte, Mark Harris, Timothy Best, Marina Johnson, Helen Wagstaffe, Elizabeth Ralph, Annabelle Mai, Caroline Colijn, Judith Breuer, Matthew Buckland, Kimberly Gilmour, David Goldblatt, the Co-Stars Study Team
doi: https://doi.org/10.1101/2020.11.20.20235697
Louis Grandjean
1Department of Infection, Inflammation and Immunity, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, UK WC1N 1EH
2Department of Infectious Diseases, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: l.grandjean@ucl.ac.uk
Anja Saso
2Department of Infectious Diseases, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
3Department of Tropical and Infectious diseases; LSHTM, Keppel St, Bloomsbury, London WC1E 7HT
4MRC Gambia at LSHTM, PO Box 273, Fajara, The Gambia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arturo Torres Ortiz
1Department of Infection, Inflammation and Immunity, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, UK WC1N 1EH
5Department of Medicine, Imperial College, Paddington, London, W2 1NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Arturo Torres Ortiz
Tanya Lam
2Department of Infectious Diseases, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Hatcher
6Department of Microbiology, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosie Thistlethwayte
7Management, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Harris
8Quality Improvement, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Best
5Department of Medicine, Imperial College, Paddington, London, W2 1NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marina Johnson
1Department of Infection, Inflammation and Immunity, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, UK WC1N 1EH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen Wagstaffe
1Department of Infection, Inflammation and Immunity, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, UK WC1N 1EH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Ralph
9Clinical Immunology, Camelia Botnar Laboratories, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annabelle Mai
9Clinical Immunology, Camelia Botnar Laboratories, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Colijn
10Department of Mathematics, Simon Fraser University, Vancouver, British Colombia, Canada BC V5A
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith Breuer
1Department of Infection, Inflammation and Immunity, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, UK WC1N 1EH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Buckland
9Clinical Immunology, Camelia Botnar Laboratories, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly Gilmour
9Clinical Immunology, Camelia Botnar Laboratories, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Goldblatt
1Department of Infection, Inflammation and Immunity, Great Ormond Street Institute of Child Health, University College London, 30 Guilford Street, London, UK WC1N 1EH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
2Department of Infectious Diseases, Great Ormond Street Hospital, Great Ormond Street, London, WC1N 3JH
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Antibodies to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) have been shown to neutralize the virus in-vitro. Similarly, animal challenge models suggest that neutralizing antibodies isolated from SARS-CoV-2 infected individuals prevent against disease upon re-exposure to the virus. Understanding the nature and duration of the antibody response following SARS-CoV-2 infection is therefore critically important.

Methods Between April and October 2020 we undertook a prospective cohort study of 3555 healthcare workers in order to elucidate the duration and dynamics of antibody responses following infection with SARS-CoV-2. After a formal performance evaluation against 169 PCR confirmed cases and negative controls, the Meso-Scale Discovery assay was used to quantify in parallel, antibody titers to the SARS-CoV-2 nucleoprotein (N), spike (S) protein and the receptor-binding-domain (RBD) of the S-protein. All seropositive participants were followed up monthly for a maximum of 7 months; those participants that were symptomatic, with known dates of symptom-onset, seropositive by the MSD assay and who provided 2 or more monthly samples were included in the analysis. Survival analysis was used to determine the proportion of sero-reversion (switching from positive to negative) from the raw data. In order to predict long-term antibody dynamics, two hierarchical longitudinal Gamma models were implemented to provide predictions for the lower bound (continuous antibody decay to zero, “Gamma-decay”) and upper bound (decay-to-plateau due to long lived plasma cells, “Gamma-plateau”) long-term antibody titers.

Results A total of 1163 samples were provided from 349 of 3555 recruited participants who were symptomatic, seropositive by the MSD assay, and were followed up with 2 or more monthly samples. At 200 days post symptom onset, 99% of participants had detectable S-antibody whereas only 75% of participants had detectable N-antibody. Even under our most pessimistic assumption of persistent negative exponential decay, the S-antibody was predicted to remain detectable in 95% of participants until 465 days [95% CI 370-575] after symptom onset. Under the Gamma-plateau model, the entire posterior distribution of S-antibody titers at plateau remained above the threshold for detection indefinitely. Surrogate neutralization assays demonstrated a strong positive correlation between antibody titers to the S-protein and blocking of the ACE-2 receptor in-vitro [R2=0.72, p<0.001]. By contrast, the N-antibody waned rapidly with a half-life of 60 days [95% CI 52-68].

Discussion This study has demonstrated persistence of the spike antibody in 99% of participants at 200 days following SARS-CoV-2 symptoms and rapid decay of the nucleoprotein antibody. Diagnostic tests or studies that rely on the N-antibody as a measure of seroprevalence must be interpreted with caution. Our lowest bound prediction for duration of the spike antibody was 465 days and our upper bound predicted spike antibody to remain indefinitely in line with the long-term seropositivity reported for SARS-CoV infection. The long-term persistence of the S-antibody, together with the strong positive correlation between the S-antibody and viral surrogate neutralization in-vitro, has important implications for the duration of functional immunity following SARS-CoV-2 infection.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04380896

Funding Statement

In line with UK government policy GOSH NHS Trust made the first diagnostic test available to all staff members in the hospital either as part of the study or outside the study. The GOSH charity provided the funding for follow up testing over the first 6 months of the study. LG declares funding from Wellcome Post-Doctoral Research Fellowship (201470/Z/16/Z). AS declares funding from Wellcome Trust Global Health Clinical Ph.D. Fellowship (220565/Z/20/Z). GOSH NHS Trust hosts a NIHR Funded Biomedical Research Centre which provides infrastructure support permitting translational research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approval for the study was granted from the Health Research Authority UK

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵† The Co-Stars Study Team: Dorcas Mirambe-Korsah Fernanda Torrente Jakub Wyszynski Victoria Gander Amy Leonard Louise Myers Aimee Vallot Camille Paillas Rose Fitzgerald Adam Twigg Rabia Manaf Lois Gibbons Hollie Powell Richard Nar-Dorh Ally Gray Elias Fernandez Aline Minja Emily Beech Waffa Girshab Pei Shi Chia Kate Webb Malti Nakrani Kim Gardiner Valerija Karaluka Karen Ryan Dorothy Lee Katie Groves Hamad Khan Shamime Nsubuga Olivia Rosie-Wilkinson Julia Spires Nuria Sanchez-Clemente Sapriya Kaur Natasha Carroll Jemma Efford Gabriel Bredin Celma Marisa Dos Santos Domingues Sophie Foxall Helen Ashton Abbey Afzal Sally Mainland Kate Crumpler Lucinda Dawson Claire Smith Maria Tabbu Laura Chiverton Jade Sugars Jordan Mooney Dorothy Chikusu Fariba Tahami Baratth Samy Shomona Begum Dhimple Patel Philippa Wiltshire Annie Susay Anna Ryan Luke Lancaster Kavita Thind Kate Speller Rachel Sterling Connor Tugulu Sandhya Ghurburrun Steffi Gray Joy Mugas Moe Kishma Kathleen Akpokomua Sophie White Eleana Pieri Sabina Shamsad Demi Alexandrou Odera Aguele Katherine Miles Anamika Jain Subishma Gautam Oliver Simms Rachel Goff Zarif Shams Tinya Chirinda Aaliya Nur Tarekur Rahman

  • The study was designed and implemented by: LG, AS, AT, TL, JH, RT, MH, TB, MJ, HW, ER, AM, CC, JB, KG, DG & the Co-Stars Team.

  • Testing for SARS-CoV-2 RNA and antibody was conducted by: LG, AS, AT, TL, JH, RT, MH, TB, MJ, HW, ER, AM, CC, JB, KG, DG

  • Funding: GOSH charity, Wellcome Trust (201470/Z/16/Z and 220565/Z/20/Z). GOSH NIHR Funded Biomedical Research Centre.

  • Trial registration number: NCT04380896.

Data Availability

Data available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 23, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2
Louis Grandjean, Anja Saso, Arturo Torres Ortiz, Tanya Lam, James Hatcher, Rosie Thistlethwayte, Mark Harris, Timothy Best, Marina Johnson, Helen Wagstaffe, Elizabeth Ralph, Annabelle Mai, Caroline Colijn, Judith Breuer, Matthew Buckland, Kimberly Gilmour, David Goldblatt, the Co-Stars Study Team
medRxiv 2020.11.20.20235697; doi: https://doi.org/10.1101/2020.11.20.20235697
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2
Louis Grandjean, Anja Saso, Arturo Torres Ortiz, Tanya Lam, James Hatcher, Rosie Thistlethwayte, Mark Harris, Timothy Best, Marina Johnson, Helen Wagstaffe, Elizabeth Ralph, Annabelle Mai, Caroline Colijn, Judith Breuer, Matthew Buckland, Kimberly Gilmour, David Goldblatt, the Co-Stars Study Team
medRxiv 2020.11.20.20235697; doi: https://doi.org/10.1101/2020.11.20.20235697

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (221)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)